Apoptosome-deficient cells lose cytochrome c through proteasomal degradation but survive by autophagy-dependent glycolysis by Ferraro, E et al.
Molecular Biology of the Cell
Vol. 19, 3576–3588, August 2008
Apoptosome-deficient Cells Lose Cytochrome c through
Proteasomal Degradation but Survive by
Autophagy-dependent Glycolysis
Elisabetta Ferraro,* Angela Pulicati,*† Maria Teresa Cencioni,‡ Mauro Cozzolino,§
Francesca Navoni,* Simona di Martino,* Roberta Nardacci,! Maria Teresa Carrı`,§¶
and Francesco Cecconi*†
*Laboratory of Molecular Neuroembryology, §Laboratory of Neurochemistry, and ‡Laboratory of
Neuroimmunology, IRCCS Fondazione Santa Lucia, 00143, Rome, Italy; †Dulbecco Telethon Institute at the
¶Department of Biology, University of Rome “Tor Vergata,” 00133 Rome, Italy; and !National Institute for
Infectious Diseases IRCCS “L. Spallanzani,” 00149 Rome, Italy
Submitted September 4, 2007; Revised May 22, 2008; Accepted June 2, 2008
Monitoring Editor: Donald D. Newmeyer
Cytochrome c release from mitochondria promotes apoptosome formation and caspase activation. The question as to
whether mitochondrial permeabilization kills cells via a caspase-independent pathway when caspase activation is
prevented is still open. Here we report that proneural cells of embryonic origin, when induced to die but rescued by
apoptosome inactivation are deprived of cytosolic cytochrome c through proteasomal degradation. We also show that, in
this context, those cells keep generating ATP by glycolysis for a long period of time and that they keep their mitochondria
in a depolarized state that can be reverted. Moreover, under these conditions, such apoptosome-deficient cells activate a
Beclin 1–dependent autophagy pathway to sustain glycolytic-dependent ATP production. Our findings contribute to
elucidating what the point-of-no-return in apoptosis is. They also help in clarifying the issue of survival of apoptosome-
deficient proneural cells under stress conditions. Unraveling this issue could be highly relevant for pharmacological
intervention and for therapies based on neural stem cell transfer in the treatment of neurological disorders.
INTRODUCTION
Apoptosome formation is the most common pathway in-
volved in apoptosis. This complex is formed when, upon
mitochondrial outer membrane permeabilization (MOMP)
caused by apoptotic inducers, cytochrome c is released from
the mitochondrial intermembrane space where it normally
resides (Liu et al., 1996; Kluck et al., 1997). In the cytoplasm,
cytochrome c binds to Apaf1 and induces its oligomeriza-
tion. Procaspase-9 is recruited to the complex and activated.
Active caspase-9, in turn, promotes activation of executioner
caspases that are responsible for the cleavage of cellular
substrates, resulting in the biochemical and morphological
changes typical of apoptosis (Li et al., 1997; Srinivasula et al.,
1998; Earnshaw et al., 1999; Saleh et al., 1999; Zou et al., 1999).
During apoptosis, MOMP allows the release of cyto-
chrome c and other proapoptotic proteins. Mitochondrial
permeabilization is regulated by proteins of the Bcl-2 family,
although its exact mechanism has not been clarified (Susin et
al., 1996; Kluck et al., 1997; Yang et al., 1997; Li et al., 1998;
Luo et al., 1998).
The absence of the apoptosome inhibits the completion of
the apoptotic process in many systems. In these conditions,
cells that have been induced to die cannot complete the
apoptotic program, even though they show some early bio-
chemical modifications that are typical of programmed cell
death and that might affect cell survival. One of them is the
release of the cytochrome c from mitochondria. Are these
modifications irreversible and do they lead invariably to cell
death, or can cells with apoptosome impairment triggered to
death still be metabolically active and therefore able to re-
cover? What is the point-of-no-return in apoptosis? These
are frequently addressed questions that remain to be clari-
fied (Martinou et al., 1999; Cozzolino et al., 2004).
The release of cytochrome c has often been considered the
point-of-no return in cell death because cytochrome c, as a
part of the mitochondrial respiratory chain, is responsible
for the generation of the mitochondrial membrane potential
(!"m). !"m is needed for various functions including the
production of ATP via oxidative phosphorylation. Perme-
abilization of the mitochondrial outer membrane and re-
lease of cytochrome c should therefore, in principle, have
a strong impact on mitochondrial function because the
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proton gradient generated by the electron transport chain
may be impaired.
However, this point is still controversial. Some reports
show that release of cytochrome c and disruption of !"m
will kill the cell in a caspase-independent way if down-
stream apoptotic effects are blocked. In fact, in cells lacking
caspase-9 or Apaf1, death is delayed but still inevitable, and
such cells are considered essentially “zombies,” i.e., severely
impaired cells that cannot be defined as living normal cells
(Ekert et al., 2004). By contrast, other studies find that cyto-
chrome c released and diffused in the cytoplasm is able to
maintain !"m and ATP generation in caspase-inhibited
cells and in Apaf1$/$ cells. This suggests that mitochondrial
recovery and cell survival are possible after the release of
cytochrome c, and therefore, that this is not the point-of-no-
return (Goldstein et al., 2000; Waterhouse et al., 2001). How-
ever, it has been reported by the same authors that the
ability to recover the !"m and to produce ATP in apopto-
some-deficient cells is possible only soon after toxic treat-
ment, whereas over time cells show a decrease of !"m
(which is considered the point-of-no-return) as well as ATP
production (Waterhouse et al., 2001).
To shed light on the ability of cells devoid of the apopto-
somal function to survive under prolonged apoptotic in-
sults, we analyzed cell metabolism in Apaf1-deprived neural
precursors (ETNA$/$ cells). We decided to use this cell
system for the following reasons: 1) The issue of proneural
cell survival is of great importance in biomedicine, because
therapies based on neural stem cell transfer are promising in
treating several neurodegenerations and one of the main
concerns regards the viability of such cells after transplan-
tation; 2) ETNA proneural cells are very sensitive to a series
of proapoptotic stimuli; and 3) we have demonstrated that
their genetic manipulation may interfere with the death
pathway without affecting their capability to grow and dif-
ferentiate in vitro (Cozzolino et al., 2004). Because it has been
suggested that the requirement and coupling of caspase-9 to
Apaf1 are both context-dependent, which means that Apaf1
and caspase-9 deficiency can have different effects on the
ability of cells to resist to apoptosis (Hakem et al., 1998; Ho
et al., 2004), we also set out to establish another apoptosome-
deficient system, i.e., a cell line overexpressing a dominant
negative form of caspase-9 (C9DNETNA cells).
We found that apoptosome-deficient proneurons, escap-
ing apoptosis induced by tunicamycin or actinomycin D,
switch to autophagy and survive through a glycolytic me-
tabolism for a long period of time before dying. In this
context, autophagy is essential to support glycolysis, ATP
production and therefore to allow cell survival. Moreover,
we found that, after its release from mitochondria, cyto-
chrome c is degraded by a proteasome-dependent mecha-
nism. These findings may be relevant to devise novel strat-
egies to improve or to reduce cell survival under stressful
conditions.
MATERIALS AND METHODS
Reagents and Plasmid Constructs
All reagents were purchased from Sigma-Aldrich (St. Louis, MO) unless
otherwise stated. MG132 and lactacystin were purchased from Calbiochem
(La Jolla, CA) and hygromycin B from GIBCO (Rockville, MD).
Wild type caspase-9 was amplified from a mouse cDNA library using the
sense primer 5#-GCAATCTCGAGGCCATGGACGAGGCGGACCGGCAG
CTCCTGC and the antisense primer 5#-AACAGCTCGAGGCCTCATG-
AAGTTTTAAAAAACAGCTTTTTC. The PCR product was cloned into
pDrive (Qiagen, Chatsworth, CA), and from there it was cut with EcoRI and
ligated into pcDNA3.1 vector (Invitrogen, Carlsbad, CA) at EcoRI site to
obtain the pcDNA3.1-C9WT expression vector. Myc-tagged cytochrome c
(pcDNA3.1Cytc-myc) was created by amplifying the cytochrome c from a
murine cDNA library using the following primers: 5#-CTATAAGCTTAC-
CATGGGTGATGTTGAAAA and 5#-CTTTGATATCCTCATTAGTAGCCTT
and by cloning the PCR product into pcDNA/3.1myc-His (Invitrogen) be-
tween the HindIII and EcoRV sites. The pcDNA3.1 plasmid coding mutant
dominant negative caspase-9 (pcDNA3.1-C9DN) was created by performing a
site-directed mutagenesis on pcDNA3.1-C9WT following the manufacturer’s
instructions (Stratagene, La Jolla, CA) through which the cysteine 325 (C325S)
of the caspase-9 active site (QACGG) was changed in serine (QASGG). For
this purpose the following primers were used: 5#-CTCTTCTTCATC-
CAAGCTTCCGGTGGTGAGCAGAAG-3# and 5#-CTTTCTGCTCACCACCG-
GAAGCTTGGATGAAGAAGAG-3#. To obtain the four mutants of myc-
tagged murine holo-cytochrome c (pcDNA3.1Cytc-mycK6R, K8R, K9R, and
K8,9R), cytochrome c cDNA was amplified from a mouse cDNA library using
four different sense primers. For pcDNA3.1Cytc-mycK6R construct: 5#-
CTATAAGCTTACCATGGGTGATGTTGAAAGAGGCAAGAAGATTTTTG-
TTCAG. For pcDNA3.1Cytc-mycK8R construct: 5#-CTATAAGCTTACCAT-
GGGTGATGTTGAAAAAGGCAGGAAGATTTTTGTTCAG. For pcDNA3.
1Cytc-mycK9R construct: 5#- CTATAAGCTTACCATGGGTGATGTT-
GAAAAAGGCAAGAGGATTTTTGTTCAG. For pcDNA3.1cytc-mycK8,9R
construct: 5#- CTATAAGCTTACCATGGGTGATGTTGAAAAAGGCAGGAG
GATTTTTGTTCAG and for all of them the antisense primer 5#-CTTT-
GATATCCTCATTAGTAGCCTT. The PCR products were cloned into
pcDNA/3.1myc-His between the HindIII and EcoRV sites.
Cell Cultures and Transfection
ETNA wild-type and ETNA$/$ cells were obtained as described elsewhere
(Cozzolino et al., 2004). They were routinely grown in DMEM (GIBCO)% 10%
FCS, at 33°C in an atmosphere of 5% CO2 in air.
To induce apoptosis, cells were treated with 20 !M actinomycin D, 5 !M
staurosporine or 3 !g/ml tunicamycin. To inhibit the proteasome, cells were
treated with 3 !g/ml tunicamycin or 20 !M actinomycin D for 24 h and then
MG132 (5 !M) or lactacystin (10 !M) were added for an additional 40 h.
Transient expression of each vector (1.5 !g DNA/3–5 & 105 cells) was
obtained with LipofectAMINE Plus reagent (Invitrogen) according to the
manufacturer’s instructions. ETNA cells stably expressing C9DNETNA were
obtained by transfecting pCDNA3.1-C9DN (1.5 !g DNA/3–5 & 105 cells)
concomitantly with a vector conferring hygromycin B resistance (0.15 !g
DNA/3–5 & 105 cells), and clones were selected by treatment with hygromy-
cin B. To discard the possible selection of clones highly resistant to caspase-
independent cell death, we performed most of the experiments using two
ETNA$/$ cell clones (ETNA$/$ and ETNA$/$C2) and two C9DNETNA
clones (C9DNETNA and C9DNETNA-C6). For preparation of mouse embry-
onic fibroblasts (MEFs), embryonic day 13.5 (e13.5) embryos from heterozy-
gous Apaf1 pregnant females were killed; the heads, viscera, and limbs were
removed, and the rest of the bodies was treated as previously reported
(Cecconi et al., 1998).
RNA Interference
Small interfering RNA (siRNA) oligonucleotides corresponding to the murine
Beclin 1 sequence were purchased from Dharmacon (siGENOME SMARTpool
M-055895, Mouse BECN1; Research, Boulder, CO). Cells (2 & 105 well) were
transfected with 100 pmol siRNA in 35-mm Petri dishes by Lipofectamine
2000 (Invitrogen) as indicated by the manufacturer. Forty-eight hours after
transfection cells were treated with tunicamycin for 48 h or left untreated.
Beclin 1 down-regulation was assessed by Western blot analysis.
Immunoprecipitation and Western Blotting
After rinsing the cultures with ice-cold phosphate-buffered saline (PBS), cell
lysis was performed in lysis buffer (20 mM Tris-HCl, pH 7.4, 1% Triton X-100,
150 mM NaCl, 1 mM EDTA, 5 mM MgCl2) containing 1 mM PMSF and a
protease inhibitor cocktail (Sigma-Aldrich). A clear supernatant was obtained
by centrifugation of lysates at 13,000 & g for 10 min. Protein content was
determined using Bradford protein assay (Bio-Rad, Richmond, CA).
For the detection of ubiquitinated cytochrome c, 100 !g of protein was
immunoprecipitated with anti-cytochrome c mAb (6H2.B4, PharMingen, San
Diego, CA) coupled to protein G-Sepharose beads (Roche, Indianapolis, IN).
Western blots were performed on polyvinylidene difluoride membranes
(Immobilon P, Millipore, Bedford, MA). Equal loading of samples was con-
firmed by "-tubulin normalization. Mouse anti-ubiquitin (Santa Cruz Biotech-
nology, Santa Cruz, CA), and rabbit polyclonal antibody raised against cyto-
chrome c (Santa Cruz Biotechnology) was used on anti-cytochrome c
immunoprecipitates for the detection of ubiquitinated cytochrome c. Cleaved
caspase-3 was detected with a polyclonal antibody against the large fragment
of activated caspase-3 (Cell Signaling, Beverly, MA). For the detection of both
full-length and cleaved active form of PARP, an anti-PARP rabbit polyclonal
antibody (Cell Signaling) was used. For the analysis of cytochrome c expres-
sion the mouse mAb anti-cytochrome c 7H8.2C12 (BD PharMingen) was used.
Polyclonal anti-caspase-9 was purchased from Cell Signaling, polyclonal an-
tibody anti-MnSOD from Stressgen (San Diego, CA), and rabbit polyclonal
anti-LC3 from Molecular Biology Laboratory (Heidelberg, Germany) and
mouse antibody anti-Beclin 1 from BD Biosciences (San Jose, CA).
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Subcellular Fractionation
Cells were harvested in hypotonic buffer (2 mM MgCl2, 10 mM KCl, 10 mM
Tris-HCl, pH 7.6) supplemented with protease inhibitor cocktail (Sigma) and
incubated for 20 min on ice. One volume of 2& Mitobuffer (450 mM sucrose,
10 mM Tris-HCl, pH 7.4, 400 !M EGTA, pH 7.4, 2 !M DTT) was added, and
the cell suspension was homogenized for 40 strokes with a Dounce homog-
enizer. Samples were centrifuged twice at 900& g for 5 min at 4°C to eliminate
cell nuclei and unbroken cells. The resulting supernatant was centrifuged at
10,000 & g for 30 min at 4°C to recover the heavy membrane pellet enriched
for mitochondria, and the resulting supernatant was stored as the cytosolic
fraction.
Immunocytochemistry
Cells cultured in 35-mm Petri dishes were washed in PBS and fixed with 4%
paraformaldehyde in PBS for 15 min. After permeabilization with 0.2% Triton
X-100 in PBS for 5 min, cells were blocked in 2% horse serum in PBS and
incubated for 1 h at 37°C with primary antibodies. We used an anti-cyto-
chrome c mouse mAb (clone 6H2.B4, BD PharMingen), an anti-caspase-9
polyclonal antibody (Cell Signaling), and a polyclonal antibody anti-MnSOD
(Stressgen). Cells were then washed in blocking buffer and incubated for 1 h
with labeled anti-mouse (Alexa Fluor 488 or Alexa Fluor 555, Molecular
Probes, Eugene, OR) or anti-rabbit (FITC or Cy3, Jackson ImmunoResearch,
West Grove, PA) secondary antibodies. After rinsing in blocking buffer, cell
nuclei were stained with 1 !g/ml DAPI and examined under a Leica TCS SP5
confocal microscope equipped with a 40& (NA 1.25) or 63& (NA 1.4) oil-
immersion objective (Deerfield, IL). Fluorescence images were adjusted for
brightness, contrast and color balance by using Adobe Photoshop CS (San
Jose, CA).
Measurement of Cellular ATP
Measurement of cellular ATP was performed using the ATPlite assay (Perkin
Elmer-Cetus, Norwalk, CY) according to the manufacturer’s instructions. In
brief, cells seeded in 96-well microplates were resuspended in 50 !l lysis
buffer, and after 5 min, 40 !l of substrate solution (Luciferase/Luciferin) was
added to each sample. The luminescence was measured using a luminescence
plate reader (Victor2 1420 multilabel counter; Wallac Oy, Turku, Finland). The
ATP concentration was standardized using the total cellular protein concen-
tration estimated by using Bradford protein assay (Bio-Rad). To confirm
results, the experiments have been repeated by normalizing the ATP content
to the number of cells.
MTS Assay
MTS Cell Titer 96AQueous One solution cell proliferation assay was per-
formed according to the supplier’s instructions (Promega, Madison, WI). The
MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-
phenyl)-2H-tetrazolium, inner salt] tetrazolium compound is bioreduced into
a colored formazan product by NADPH or NADH produced by dehydroge-
nase enzymes in metabolically active cells. Cells were plated in triplicate in
96-well plates at 3–7 & 103 cells per well. After treatment, Cell Titer 96AQue-
ous One solution was added to each well for 90 min, and the light absorbance
at 490 nm was recorded using a 96-well plate reader (Wallac Oy; Victor2 1420
multilabel counter). Values were normalized by protein content or by number
of cells.
Assessment of !"m
!"m was measured using tetramethylrhodamine ethyl ester (TMRE, Molec-
ular Probes). Cells were incubated at 33°C for 15 min in media containing
TMRE (50 nM). As a control for !"m dissipation, cells were treated with 10
!M carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone (FCCP). Cells
were then rinsed in fresh medium and detached from the dish. TMRE fluo-
rescence was detected by flow cytometry on a FACScan (Becton Dickinson,
Franklin Lakes, NJ) in FL-2.
Measurement of Reactive Oxygen Species Production
The reactive oxygen species (ROS)-sensitive probe DCF-DA (2#,7#-dichlorodi-
hydrofluorescein-diacetate; 30 !M) was added directly to the culture medium
for 1 h. Cells were washed with PBS and analyzed immediately by flow
cytometry using the FITC channel on a FACScan (Becton Dickinson).
Oxygen Consumption Measurement in Intact Cells
The respiration rate was measured by a Clark oxygen electrode (Gilson
Medical Electronics, Middleton, WI; 3000 W Mod 5/6 H). Cells were injected
in a thermojacketed chamber containing 1650 !l TD buffer (25 mM Tris-HCl,
pH 7.4, 137 mM NaCl, 10 mM KCl, 0.7 mM Na2HPO4) prewarmed at 33°C.
Respiration was driven by endogenous substrates. After obtaining a stable
rate, oligomycin and then bongkrekic acid were added. After blocking com-
plex III with antimycin A, the cytochrome c oxidase–dependent oxygen
consumption rate (obtained by addition of N,N,N#,N#-tetramethyl-p-phenyl-
enediamine, TMPD % ascorbate) was inhibited by KCN or NaN3 (Duan et al.,
2003). Rates of oxygen consumption are expressed as nanograms atoms of
oxygen per minute per milligram proteins.
Electron Microscopy
Cells were fixed with 2.5% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4,
for 45 min at 4°C, rinsed in cacodylate buffer 0.1 M, pH 7.4, postfixed in 1%
OsO4 in 0.1 M cacodylate buffer, pH 7.4, dehydrated, and embedded in Epon.
Ultrathin sections were briefly contrasted with uranyl acetate and photo-
graphed in a Zeiss EM 900 electron microscope (Thornwood, NY).
Statistical Analysis
Microsoft Excel was used for statistical analysis (Redmond, WA). Statistical
significance was determined using the Student’s t test; p # 0.05 was consid-
ered significant.
RESULTS
Dissection of the Role of the Apoptosome Components:
Apaf1-deficient Cells (ETNA#/#) and C9DNETNA Are
Resistant to Apoptosis
Our purpose was to analyze in detail the behavior of cells
devoid of the apoptosome under prolonged apoptotic in-
sults. We had previously established a cell line in which
Apaf1 is deleted (ETNA$/$) and that is therefore unable to
form the apoptosome. We had already proved the resistance
of ETNA$/$ cells to several apoptotic stimuli (Cozzolino et
al., 2004). For this work, we also produced a cell line ex-
pressing a mutant form of murine caspase-9 acting as dom-
inant negative (C9DNETNA). To this aim, we performed a
site-directed mutagenesis of the caspase-9 active site
(QACGG) in which the cystein 325 was changed in serine
(QASGG). This form of mutant caspase-9 is able to bind
Apaf1 and to allow the formation of the apoptosome; how-
ever, it does exert a dominant negative influence on effector
caspase activation and apoptosis (Li et al., 1997). As shown
in Figure 1A, transient transfection of an expression vector
encoding dominant negative caspase-9 (C9DN), in ETNA
cells followed by treatment with tunicamycin (an inhibitor
of N-linked glycosylation and of the formation of N-glyco-
sidic protein-carbohydrate linkages), induces decreased ac-
tivation of caspase-3 as well as a reduced cleavage of PARP,
if compared with untransfected ETNA cells (Untr) or with
ETNA cells overexpressing wild-type caspase-9 (C9WT). We
therefore established a second apoptosome-deficient system,
i.e., ETNA cells stably overexpressing C9DN (C9DNETNA),
in which the formation of the apoptosome is allowed but
caspase-9 is mutated and therefore enzymatically inactive
(Figure 1, B and C). We demonstrated that not only
ETNA$/$ cells but also C9DNETNA cells are protected
from apoptosis because treatment with tunicamycin or with
actinomycin D (an inhibitor of mRNA transcription) does
not produce nuclear fragmentation (Figures 1C and 2A and
data not shown), PARP cleavage or caspase-3 activation
(Figure 1D and data not shown). The same results were
obtained upon treatment with staurosporine, a widespread
protein kinase inhibitor (data not shown).
Cytochrome c Is Degraded by a Proteasome-dependent
Mechanism Once It Is Released from Mitochondria in
Both ETNA#/# and C9DNETNA Cells
By using ETNA$/$ and C9DNETNA cells we wanted to
evaluate the possibility and the modality of recovery of cells
receiving apoptotic stimuli in the absence of the apopto-
some. To answer this question, we analyzed some metabolic
parameters of ETNA$/$ and C9DNETNA cells under apo-
ptotic induction.
The first event in the apoptotic process we wanted to
check was the release of cytochrome c. This molecule is
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extremely relevant both for cell metabolism and for the
apoptotic process. When ETNA$/$cells are treated for
48 h with tunicamycin or actinomycin D, cytochrome c is
released from mitochondria, and it is found diffused in
the cytosol and in the nucleus (Figure 2A and not shown).
However, cytochrome c staining disappears upon longer
treatment with apoptotic inducers (72 h), whereas mito-
chondria staining, as revealed by detection of two mito-
chondrial resident proteins (MnSOD and Hsp60), is main-
tained (Figure 2A and data not shown). This observation
is confirmed by a time-course evaluation of the amount of
cytochrome c performed by Western blot (Figure 2B): after
72 h of both treatments, cytochrome c completely disap-
pears.
In ETNA$/$ cells, cytochrome c released in the cytosol
cannot bind the apoptosome because its partner Apaf1 is
absent. To elucidate whether cytochrome c degradation
takes place in the presence of Apaf1, we checked the
amount of cytochrome c in C9DNETNA cells upon apo-
ptotic induction. Again, after a prolonged treatment, a
considerable number of cells display a complete loss of
cytochrome c staining (Figure 3A, 60 h); this evidence is
confirmed by Western blot analysis on total extracts and
on mitochondrial/cytosolic fractions (Figure 3, B, 60 h,
and C, 72 h).
These observations led us to hypothesize a role for the
ubiquitin-proteasome machinery in the disappearance of
cytochrome c. To assess this possibility, we treated the cells
with proteasome inhibitors, namely lactacystin or MG132,
during the apoptotic stimulation. In particular, we exposed
the cells to the apoptotic inducers (tunicamycin or actino-
mycin D), and after 24 h, we added the proteasome inhibitor.
By immunofluorescence, we observed a significant amount
of cytochrome c in the cytosol of cells induced to die and
treated with the proteasome inhibitor MG132 (Figure 3A, 60
hMG). Western blot analysis also revealed a considerable
increase in the steady-state level of cytochrome c in the
presence of MG132 (Figure 3, B and C). Taken together these
results suggest that, after its release from mitochondria,
cytochrome c is degraded by the proteasome. The fact that
we obtained the same regulation of degradation both in
ETNA$/$ and C9DNETNA indicates that cytochrome c
degradation in the cytosol does not depend on its binding to
Apaf1.
Figure 1. ETNA cells overexpressing a dominant negative form of
caspase-9 (C9DNETNA) are resistant to apoptotic stimuli. (A) Total
cell lysates from untransfected ETNA cells (Untr), ETNA cells tran-
siently transfected with dominant negative caspase-9 (C9DN) or
ETNA cells transiently transfected with wild-type caspase-9 (C9WT)
untreated (Ctrl) or treated for 40 h with 3 !g/ml tunicamycin (Tun)
were subjected to SDS-PAGE and analyzed for caspase-3 processing
and for PARP processing. (B) Western blot analysis of caspase-9
expression in untransfected ETNA cells (ETNA) or ETNA cells
stably overexpressing caspase-9 (C9DNETNA). (C) Triple-labeling
immunofluorescence microscopy of ETNA and C9DNETNA cells
treated for 40 h with 3 !g/ml tunicamycin (Tun). Cytochrome c
(green), caspase-9 (red), nuclear staining (DAPI, blue), and merge of
the three patterns are shown. ETNA cells show release of cyto-
chrome c and extensive nuclear fragmentation (white arrows),
whereas C9DNETNA cells exhibit released cytochrome c but unaf-
fected nuclei (white arrows). Notice that in the immunofluorescence
assay the used anti-caspase-9 antibody (which can recognize both
the procaspase-9 and its cleaved form) enables caspase-9 detection
only upon its overexpression (in C9DNETNA cells). Scale bar, 20
!m. (D) Western blot analysis of caspase-3 processing and PARP
processing in total lysates of ETNA, C9DNETNA, and ETNA$/$
cells untreated (Ctrl) or treated with tunicamycin (Tun) as described
before. Immunoblot detection of "-tubulin is used as control of
equal protein loading.
Figure 2. Cytochrome c detection, in ETNA$/$ cells, is abolished
after long treatment with tunicamycin or actinomycin D. (A) Dou-
ble-labeling confocal immunofluorescence microscopy of ETNA$/$
cells untreated (Ctrl) or treated for 48 or 72 h with 3 !g/ml tunica-
mycin (Tun). Merged patterns of cytochrome c (green), MnSOD
(red), and nuclei (DAPI, blue; top panels), and merged patterns of
cytochrome c (green) and MnSOD (red) without nuclear staining of
the same fields are shown (bottom panels). White arrows point to
cells with released cytochrome c. White arrowheads point to cells
with degraded cytochrome c. Scale bar, 20 !m. (B) Time-course
analysis of cytochrome c expression in total cell lysates of ETNA$/$
cells treated with 3 !g/ml tunicamycin (Tun) or 20 !M actinomycin
D (ActD). 'nSOD was also assayed as a control of equal protein
loading.
Apoptosis Inhibition and Autophagy
Vol. 19, August 2008 3579
Previous evidence indicates that both forms of Saccha-
romyces cerevisiae cytochrome c (iso-1 and -2) can be ubi-
quitinated and that the major and minor ubiquitination
sites are, in both proteins, Lys10 and Lys5, respectively
(Sokolik and Cohen, 1991). Ubiquitination of apo-iso-1
(but not apo-iso-2) causes its rapid degradation through
the proteasome pathway in the cytosol, when its import
into the mitochondria and its maturation are blocked.
Furthermore, apo-iso-1 was found to be ubiquitinated by
overexpressing HA-tagged ubiquitin (Pearce and Sher-
man, 1997; Sherman, 2005).
To check whether ubiquitination of holo-cytochrome c
occurs in mammals, we performed immunoprecipitation of
C9DNETNA cell extracts using a monoclonal anti-cyto-
chrome c antibody. Western blot on the cytochrome c im-
munoprecipitates (IPs) was then performed by using a poly-
clonal antibody anti-cytochrome c or a polyclonal antibody
anti-ubiquitin (Figure 3D). We observed a band around 27
kDa (arrows) that is a putative ubiquitinated cytochrome c,
because it is recognized both by anti-cytochrome c and by
anti-ubiquitin antibodies. However, Lys6, Lys8, and Lys9
(corresponding to Lys10 and the Lys5 in yeast) are not in-
volved in the ubiquitination of mammalian cytochrome c
(Figure S1).
Under Proapoptotic Treatment, in the Absence of
Cytochrome c, Apoptosome-Null Cells Are Able to
Produce ATP Although They Have Depolarized
Mitochondria
Our next goal was to detect the modalities of surviving of
ETNA$/$ and C9DNETNA cells without cytochrome c.
First of all we wanted to check if such cells survive fully or
if they are merely cells on the verge of death (“zombies”;
Ekert et al., 2004). For this purpose, we analyzed some as-
pects of their metabolism by measuring the amount of ATP
produced in normal conditions, under apoptotic stimulation
and under prolonged apoptotic treatment.
As shown in Figure 4 and Figure S2, ATP production is
increased after 24–48 h of treatment with either tunicamycin
or actinomycin D. Longer treatments induce a relative de-
crease in ATP levels; however, even after many hours from
the apoptotic stimulus application, the level of ATP pro-
duced remains high if compared with wild-type ETNA cells.
This demonstrates that apoptosome-deficient cells under ap-
optotic induction are metabolically active for a long time,
even in absence of cytochrome c (Figure 4 and Figure S2).
Ultimately, the cells start dying (after 120–144 h of treat-
ment, depending on the cell line) as shown by very low ATP
production (Figure S2) and loss of membrane integrity, as
detected by trypan blue staining (Figure S3). By contrast, as
expected, in wild-type ETNA cells there is a strong decrease
in ATP production, starting already after a 48-h treatment
(see Figure S2).
We also evaluated the production of NADH and
NADPH by dehydrogenase enzymes (MTS assay, FACS
analysis, and 340-nm absorbance measurement), this be-
ing an indication of metabolically active cells. Again, even
though cells lose cytochrome c, a high metabolic activity is
maintained for a long time in both ETNA$/$ and
C9DNETNA cells treated with tunicamycin or actinomy-
cin D (Figure 4B and Figure S4). To confirm these findings,
the production of reducing equivalents has been normal-
ized both to the amount of protein and to the number of
cells (Figure 4B and Figure S4A).
To discard the possible selection of clones highly resistant
to caspase-independent cell death, we performed the exper-
iments using another ETNA$/$ clone (ETNA$/$C2) and
another C9DNETNA clone (C9DNETNA-C6; Figures S2, S3,
and S4A). We also performed the same experiments using
another cell type (Apaf1$/$ MEFs), obtaining similar results
(Figure S4A).
We wondered how ETNA$/$ and C9DNETNA cells were
able to produce a high amount of ATP in the absence of
Figure 3. Cytochrome c is ubiquitinated and degraded by a
proteasome-dependent mechanism after long apoptotic treat-
ment in both ETNA$/$ and C9DNETNA cells. (A) Double-label-
ing confocal immunofluorescence microscopy of ETNA$/$ cells
and C9DNETNA cells treated with 3 !g/ml tunicamycin (Tun) or
20 !M actinomycin D (ActD) for 60 h and cells under the same
treatments plus 2 !M MG132 (60 hMG) added after 24 h of apopto-
tic inducer treatment. Merged patterns of cytochrome c (green) and
nuclei (DAPI, blue) or merged patterns of cytochrome c (green) and
MnSOD (red) are shown. Scale bar, 20 !m. (B) Western blot analysis
of cytochrome c expression in total cell lysates of ETNA$/$ cells
and C9DNETNA cells untreated (Ctrl) or treated with tunicamy-
cin (60 h) or with tunicamycin plus MG132 (60hMG). MnSOD
was also assayed as a control of equal protein loading. (C)
Cytosolic (Cyt) and membrane (M) fractions of ETNA$/$ cells
and C9DNETNA cells untreated (Ctrl) or treated with tunicamy-
cin (72 h) or with tunicamycin and MG132 (72hMG) were ana-
lyzed by Western blot for the presence of cytochrome c. MnSOD
was used as a control of equal protein loading in the membrane
fractions. (D) Cytochrome c was immunoprecipitated from
C9DNETNA cell extracts (100 !g) with a mAb (IP:anti-Cyt c).
Total extracts (T), supernatants from the immunoprecipitates (S),
and immunoprecipitates (IP) were then probed with an anti-
ubiquitin antibody (WB:anti-Ubiq) or with a rabbit antibody
raised against cytochrome c (WB:anti-Cyt c). The arrows indicate
the position of ubiquitinated cytochrome c.
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cytochrome c. To investigate the possibility that some cyto-
chrome c might still be located within mitochondria and
support the respiratory chain, we measured !"m by incu-
bation with TMRE and FACS analysis. We used FCCP, an
uncoupler that dissipates the transmembrane potential by
preventing the generation of a proton gradient, as a control
for depolarized mitochondria. As reported in Figure 5A,
during apoptotic induction there is a marked depolarization
of mitochondria (Tun, red line). This is in contrast with other
parameters, such as levels of ATP and reducing equivalents,
that are well maintained. This fall in !"m is progressive
during both tunicamycin and actinomycin D treatment (Fig-
ure 5A and not shown).
Figure 4. Both ETNA$/$ and C9DNETNA cells are metabolically
active after prolonged apoptotic treatment as seen by ATP content
and MTS assay. (A) ATP production in ETNA$/$ and C9DNETNA
cells treated with 3 !g/ml tunicamycin (Tun) or 20 !M actinomycin
D (ActD) for the times indicated. A.U., arbitrary units. The ATP
content has not been normalized for the amount of protein, but it
has been evaluated after seeding and treating the same number of
cells for each condition. (B) Reducing equivalent production mea-
sured by MTS-formazan assay in ETNA$/$ and C9DNETNA cells
treated with tunicamycin (Tun) or actinomycin D (ActD) for the
times indicated. Values represent the mean ( SD of four experi-
ments.
Figure 5. Under apoptotic treatment, apoptosome-null cells pro-
gressively dissipate !"m in the absence of cytochrome c. (A)
ETNA$/$ and C9DNETNA cells untreated (Ctrl, green line), treated
with 10 !M FCCP (FCCP, blue line) as a control for mitochondrial
depolarization, or treated with tunicamycin for 48 or 64 h (Tun,
red line) were stained with TMRE (50 nM) for 10 min, washed,
and then analyzed by FACS analysis for !"m. ETNA$/$ and
C9DNETNA cells untreated or treated with tunicamycin for 48 or
64 h were incubated with oligomycin (2 !M) for 10 min (%Olig,
black line) before TMRE staining. (B) Before TMRE staining (50
nM) and FACS analysis, C9DNETNA cells were left untreated
(Ctrl, green line), treated with 10 !M FCCP (FCCP, blue line), or
treated for 5 min with 20 !M antimycin A (Ctrl%Ant), 5 mM
KCN (Ctrl%KCN), or 10 mM NaN3 (Ctrl%NaN3; Tun%Inh.%Olig,
gray shadow). C9DNETNA cells treated with tunicamycin for 48 h
(Tun, red line) were then treated for 2 min with 20 !M antimycin A
(Tun%Ant%Olig), 5 mM KCN (Tun%KCN%Olig), and 10 mM NaN3
(Tun%NaN3%Olig). C9DNETNA cells treated with tunicamycin for
44 h (Tun, red line) were then treated for 2 min with 50 !M
bongkrekic acid (Tun%Bong%Olig). In all cases cells were finally
incubated with oligomycin (2 !M) for 10 min before TMRE staining
(gray shadow).
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In conclusion, if cells induced to die do not undergo
apoptosis because of the absence of a functional apopto-
some, they are still able to maintain a high metabolism (for
many days before dying), as seen by measurement of ATP
and reducing equivalent production. This occurs even
though cytochrome c has been released and degraded and
!"m has been lost.
On Apoptotic Treatment, Cell Metabolism in the Absence
of Cytochrome c Is Maintained by Glycolysis
Next, we wanted to determine how cells maintain high ATP
levels and high metabolic activity despite a loss of cyto-
chrome c and a null !"m, both of which suggest a mito-
chondrial impairment. Thus, we decided to study the con-
tribution of glycolytic and mitochondrial metabolism to ATP
production. To address this issue, we blocked the F0F1-
ATPase with oligomycin to inhibit the production of ATP
based on the respiratory chain, and therefore we measured
ATP produced by glycolysis only.
When we treated ETNA$/$ and C9DNETNA cells under
apoptotic stimulation with oligomycin, we did not observe
any decrease in the ATP production (Figure 6 and Figure S5,
u). This strongly suggests that in cells under apoptotic stim-
ulation ATP is supplied mainly by the glycolytic metabo-
lism. In fact, under the same conditions we also inhibited
glycolysis by removing glucose and serum from the medium
(to allow complete removal of intermediates of glycolysis)
and by adding methylpyruvate (Mpyr, a cell permeable
form of pyruvate) to sustain the electron-transport chain,
and we detected a strong decrease in the amount of ATP
produced starting after 48 h of tunicamycin treatment (Fig-
ure 6 and Figure S5, f). After a 24-h treatment, ATP is still
produced even under conditions of inhibited glycolysis by
oxidative phosphorylation (Figure 6 and Figure S5, f) be-
cause cytochrome c is still within mitochondria (data not
shown). Tunicamycin treatment requires, in fact, at least 40 h
to kill wild-type ETNA cells (Figure 1). Because the removal
of serum could be stressful for the cells and could induce
additional events that may interfere with the experiment, we
repeated all the assays by blocking glycolysis using dialyzed
serum, and we obtained exactly the same results (data not
shown). To extend our findings to another cell type, we
performed the same experiments in Apaf1$/$ MEFs, obtain-
ing similar results (Figure S6).
This experiment demonstrates that, in both ETNA cell
systems and in another apoptosome-deficient cell system,
during the apoptotic treatment there is a production of ATP
almost exclusively due to the glycolytic metabolism.
Similarly, the reducing equivalent production in
ETNA$/$ and C9DNETNA treated with tunicamycin and
Figure 6. On apoptotic treatment, ATP production is
supported by glycolysis. (A) Gray bars, ATP production
in wild-type ETNA cells grown in 10% FBS medium
and left untreated (Ctrl) or treated with 3 !g/ml tuni-
camycin for the given time periods, and ATP produc-
tion in ETNA cells under the same treatments and in-
cubated for the last 20 min with 2 !M oligomycin (Olig)
are shown. Black bars, ATP production in ETNA cells
left untreated (Ctrl) or treated with 3 !g/ml tunicamy-
cin for the indicated time periods in complete medium
is shown. In this case, 2 h before ATP measurement,
glycolysis was inhibited by incubating cells in a me-
dium without glucose, without serum, and with 10 mM
Mpyr ($gluc-serum%Mpyr) with (Olig) or without 2
!M oligomycin addition for the last 20 min. A.U., arbi-
trary units. The experiment was done by seeding and
treating the same number of cells for each condition. (B)
Same as A but in ETNA$/$ cells. (C) Same as A but in
C9DNETNA cells. Data shown represent the mean (
SD of three experiments.
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measured by MTS assay was not affected by oligomycin
(Figure 7). This indicates that such production depends on
glycolysis. In Figure S5 the ATP content was normalized
both to the number of cells and to the amount of protein to
strengthen the data.
Mitochondria Are Not Irreversibly Impaired under
Apoptotic Treatment, and the Recovery of !"m Is
Dependent on Active Glycolytic Metabolism
Next, we wanted to assess if depolarized mitochondria of
cells induced to apoptosis and surviving mainly by glycol-
ysis were irreversibly impaired.
Treatment with oligomycin is able to hyperpolarize mito-
chondria in control cells because the proton gradient is not
used to produce ATP (Figure 5A). Impaired mitochondria
cannot undergo oligomycin-induced hyperpolarization. Un-
der tunicamycin treatment, cells display a bimodal distribu-
tion with respect to TMRE fluorescence. One population is
formed by cells with a normal !"m and another population
(growing in number during the treatment) exhibits depolar-
ized mitochondria. When such tunicamycin-treated cells are
incubated with oligomycin, both populations are able to
hyperpolarize. Not only cells displaying normal !"m, but
even cells that have lost !"m are able to regain it (Figure
5A). These data suggest that depolarized mitochondria have
not reached a point-of-no-return, and are capable of repo-
larization.
We observed that, in tunicamycin-related cells, oligomy-
cin-induced regeneration of !"m is insensitive to anti-my-
cin A, which impairs the respiratory chain by blocking com-
plex III, and to KCN or NaN3, which are both inhibitors of
complex IV (Figure 5B and Figures S7 and S8). This suggests
that !"m might be regenerated in the absence of respiratory
chain activity. A similar mechanism, allowing !"m in the
absence of a functional electron transport chain, has been
shown to function in rho zero cells (Buchet and Godinot,
1998). Interestingly, the adenine nucleotide translocator
(ANT) inhibitor, bongkrekic acid, partially impairs oligomy-
cin-induced regeneration of !"m in tunicamycin-treated
cells (Figure 5B).
When we blocked ATPase with oligomycin under condi-
tions of inhibited glycolysis, we observed hyperpolarization
of control cells (Figure 8, black line, Ctrl) and of the cell
population displaying intact !"m under tunicamycin treat-
ment (Figure 8, black line, 48 h). In contrast with the previ-
ous experiment, done in presence of serum and glucose
(Figure 5A, black line), depolarized cells were not able, in
this case, to recover their !"m (Figure 8, black line).
This experiment indicates that without glycolysis, apopto-
tic treatment and opening of mitochondrial outer membrane
irreversibly affect mitochondria. However, when glycolysis
is active, mitochondria are depolarized but are still capable
of repolarization.
Glycolysis Inhibition Induces an Increased Production of
ROS and Blocks Cell Recovery
Glycolysis might be important to allow mitochondrial recov-
ery because it supplies the ATP necessary to allow !"m
regeneration by a mechanism similar to the one hypothe-
sized for rho zero cells (Buchet and Godinot, 1998). How-
ever, this might not be the only role of glycolysis. To assess
why glycolysis protects mitochondrial function, we have
measured ROS production. For this purpose, we used the
ROS-sensitive probe DCF. We observed that when glycoly-
sis is inhibited, there is a high production of ROS both in
untreated (Ctrl) and in tunicamycin-treated cells (48 h) in-
dependently on the cell line we analyzed (Figure 9). Because
ROS impair mitochondrial function (Ott et al., 2007), the
increased ROS production might contribute to explaining
(besides the lack of ATP) why !"m, in the absence of
glycolysis, is unable to recover.
We also found out that, if glycolysis is functional, apop-
tosome-deficient cells after cytochrome c release might re-
cover and proliferate but only if the apoptotic stimulus is
Figure 7. On apoptotic treatment, glycolysis sustains the produc-
tion of NADH and NADPH by dehydrogenase enzymes (MTS
assay). MTS assay in ETNA$/$ and C9DNETNA cells grown in 10%
FBS medium and left untreated (Ctrl) or treated with 3 !g/ml
tunicamycin (Tun) for the indicated time periods with or without 2
!M oligomycin addition for the last 20 min (Olig). Normalization
was done to the amount of protein. Data shown represent the
mean ( SD of three experiments.
Figure 8. Recovery of !"m, under apoptotic treatment of apop-
tosome-null cells, is dependent on active glycolytic metabolism.
ETNA$/$ cells and C9DNETNA cells untreated (Ctrl, green line),
treated with 10 !M FCCP (FCCP, blue line) or treated with tunica-
mycin for 48 h (Tun, red line) were deprived of glucose and serum
and were supplied with Mpyr 2 h before TMRE staining and FACS
analysis. ETNA$/$ cells and C9DNETNA cells untreated or treated
with tunicamycin (Tun) for 48 h, were incubated with oligomycin (2
!M) for 10 min (%Olig, black line) before TMRE staining.
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removed within a certain time range after induction (Figure
10). After 48 h of treatment, when the large majority of cells
had released cytochrome c, tunicamycin was washed out.
Medium was replaced with complete medium without tu-
nicamycin, and cells were kept in these conditions for addi-
tional 24 h (72 h-washed), 48 h (96 h-washed), 96 h (120 h-
washed), and 120 h (144 h-washed). Mitochondrial recovery
(indicated by mitochondrial cytochrome c localization), cell
survival, and cell proliferation were analyzed. After 72–96 h
of tunicamycin treatment, cells appeared shrunk and were
mostly detached. Their cytochrome c was released and de-
graded (Figure 10A). At 120–144 h, cells were all detached,
and they incorporated trypan blue, which stains only dead
cells (Figure S3). By contrast, cultures washed at 48 h and
observed at 72, 96, and 120 h showed 1) an increasing
number of cells containing cytochrome c in their mitochon-
dria, 2) absence of cell shrinkage (72 h, 96 h washed com-
pared with not washed cells), and 3) an increasing number
Figure 10. Relocalization of cytochrome c, recovery and prolifer-
ation of tunicamycin-treated cells upon removal of the apoptotic
induction. (A) ETNA$/$ cells were treated with 3 !g/ml tuni-
camycin (Tun, 72 and 96 h). In parallel, ETNA$/$ cells treated
with 3 !g/ml tunicamycin were washed after 48 h of treatment
and medium was replaced with complete medium without tuni-
camycin (Tun%wash). Cells were kept in these conditions for
additional 24 h (72 h-washed), 48 h (96 h-washed), 96 h (120
h-washed), and 120 h (144 h-washed). (B) ETNA$/$ cells were
treated with 3 !g/ml tunicamycin; after 48 h of treatment, cells
were washed, and medium was replaced with medium deprived
of glucose and serum and were supplied with Mpyr, without
tunicamycin (Tun%wash, no glycolysis). Cells were kept in these
conditions for additional 24 h (72 h-washed-no glyc) and 48 h (96
h-washed-no glyc). Under these conditions, cells appeared
shrunk and most of them were detached. After additional 96 h,
cells were completely detached (not shown). Detection by immu-
nofluorescence of cytochrome c localization (green) and nuclear
DAPI staining (blue) is shown.
Figure 9. ROS production increases in absence of glycolysis.
ETNA$/$, C9DNETNA ETNA$/$C2, C9DNETNA-C6, and
Apaf1$/$ MEFs untreated (Ctrl), or treated for 48 h with tunicamy-
cin (Tun), were cultured in complete medium (black line) or were
deprived of glucose and serum and were supplied with Mpyr (gray
shadow) 2 h before ROS measurement by FACS analysis. One hour
before FACS analysis, cells were incubated with the ROS-sensitive
probe DCF (30 !M). As negative control, cells cultured in complete
medium were not incubated with DCF (red line).
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of cells attached to the dish. However, waiting 72 h to wash
the cells, or blocking glycolysis, inhibited cell recovery (Fig-
ure 10B and data not shown).
The Glycolytic Metabolism of ETNA#/# and C9DNETNA
Cells under Apoptotic Induction Is Based on Beclin
1–dependent Autophagy
Autophagy is a self-degradative process involved both in basal
turnover of cellular components and in response to nutrient
starvation or organelle damage in a wide range of eukaryotes
(Levine and Yuan, 2005). Because ETNA$/$ and C9DNETNA
cells produce ATP through glycolysis when cytochrome c is
released, and because autophagy is a way to resist death, we
decided to test if autophagy played a role in the maintenance of
ATP production under these conditions. The occurrence of
autophagy was analyzed by assessing 1) the increased number
of autophagosomes (autophagic vesicles) by electron micros-
copy and 2) the conversion of microtubule-associated protein 1
light-chain 3 (LC3)-I (18 kDa) in the lipidated form LC3-II (16
kDa), essential for its binding to the membranes of autophago-
somes (Ferraro and Cecconi, 2007). We observed that wild-type
ETNA, ETNA$/$, and C9DNETNA cells under apoptotic
treatment clearly undergo autophagy. In fact, in contrast with
untreated cells, we detected many autophagic vesicles in both cell
lines treatedwith tunicamycin (Figure 11A) or actinomycinD (not
shown). In addition, we observed an increase of the LC3-II band,
whose relative amount reflects the abundance of the autophago-
somes (Figure 11B). Both these autophagic markers are detectable
soon after the apoptotic treatment. Very interestingly, when au-
tophagy is suppressed by siRNA, silencing the proautophagic
gene Beclin 1 in tunicamycin-treated ETNA$/$ andC9DNETNA
cells, there is a marked decrease in the production of ATP (Figure
11, C and D, and data not shown) and an earlier death of apop-
tosome-deficient cells, as suggested by the increased trypan blue
staining (Figure 11E and data not shown).
DISCUSSION
The apoptotic process is very well regulated at different
levels to prevent uncontrolled cell death; one of the strate-
gies used by the cell to control programmed cell death is to
hide proapoptotic factors inside mitochondria. Protein sta-
bility is another key regulatory mechanism in the control of
several cellular processes including apoptosis. Several apo-
ptotic proteins are, indeed, degraded by the ubiquitin-pro-
teasome pathway (Argentini et al., 2000; Suzuki et al., 2001;
Wilson et al., 2002; Zhang et al., 2004). During mitochondria
turnover there could be risk of release of small amount of
proapoptotic factors residing in the intermembrane space,
including cytochrome c. This would prime an unwanted
Figure 11. The glycolytic metabolism of ETNA$/$
and C9DNETNA cells under apoptotic treatment is
based on Beclin 1–dependent autophagy. (A) Ultra-
structural features by means of electron microscopy
were observed in ultrathin sections from ETNA$/$ and
C9DNETNA cells untreated (Ctrl) or treated with 3
!g/ml tunicamycin (Tun; 24 h). Numerous autophagic
vacuoles (black arrows) and dilation of endoplasmic
reticulum (ER) are visible in the cytoplasm of tunicamy-
cin-treated cells. The prolonged treatment (Tun; 48 h)
enhances autophagic vacuole formation (black arrows).
N, nucleus; M, mitochondrion; ER, endoplasmic reticu-
lum. Scale bar, 1 !m. (B) Western blot analysis of LC3-I
to LC3-II conversion in total lysates of ETNA$/$,
C9DNETNA, and wild-type ETNA cells untreated (Ctrl)
or treated with 3 !g/ml tunicamycin for 33 h (Tun). (C)
Western blot analysis of Beclin 1 amount in ETNA$/$
cells (WT) and in ETNA$/$ cells transiently transfected
for 48 h with siRNA duplex against Beclin 1 mRNA
(siRNABec1) treated with 3 !g/ml tunicamycin for fur-
ther 48 h (Tun) or left untreated for the same time (Ctrl).
(D) ATP content in ETNA$/$ cells (WT) and in
ETNA$/$ cells transiently transfected with siRNA du-
plex against Beclin 1 (siRNABec1) and treated with 3
!g/ml tunicamycin for 48 h (Tun) or left untreated
(Ctrl) for the same time was measured. Values in D
represent the mean ( SD of three experiments. (E)
Representative images of trypan blue staining of
C9DNETNA cells (WT) and C9DNETNA cells tran-
siently transfected with siRNA duplex against Beclin 1
(siRNABec1) and treated with 3 !g/ml tunicamycin for
96 h (Tun) or left untreated (Ctrl) for the same time.
Percentage of trypan blue–incorporating cells were de-
termined by counting )1000 cells (per each condition
and per each experiment) and calculating the average of
three independent experiments ( SD.
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apoptotic pathway. To avoid this, it has been proposed that
there must be a threshold of cytochrome c to be reached in
order to activate the apoptosome (Waterhouse et al., 2002).
Indeed, in our model we have observed a proteasome-de-
pendent degradation of cytochrome c released in the cytosol.
In this scenario, the degradation of cytochrome c once in the
cytosol may represent a mechanism needed to prevent acci-
dental apoptosis, as already reported for other mitochon-
drial proapoptotic factors such as Smac/DIABLO (MacFar-
lane et al., 2002).
Moreover, it has been reported that, in the absence of
caspase activation, mitochondria remain functional after mi-
tochondrial permeabilization by using the low levels of cy-
tochrome c released into the cytosol to regenerate !"m
(Waterhouse et al., 2001). In glucose-deprived and Mpyr-
provided cells, the maintenance of !"m ensured mitochon-
drial ATP generation, making it possible for these cells to
survive after MOMP. However, this effect was only tempo-
rary because ATP levels dropped after more than 12 h of
actinomycin D treatment. In this context, the inhibition of
cytochrome c degradation could help cells to maintain mi-
tochondrial ATP production and to recover from the apo-
ptotic insult. In fact, it has been shown that readdition of
cytochrome c in digitonin-permeabilized cells was able to
restore !"m in cells induced to undergo apoptosis in the
presence of caspase inhibitors (Waterhouse et al., 2001).
Considering the importance of cytochrome c in the meta-
bolic activity of cells and hence in their survival, we set out
to establish whether in mammalian cells holo-cytochrome c
was degraded after ubiquitination and, if so, to identify the
ubiquitin attachment sites on the protein. The inhibition of
cytochrome c ubiquitination and degradation upon its re-
lease into the cytosol during apoptotic stimulation could be
a tool to support the survival of cells. By immunoprecipitat-
ing cytochrome c from cell lysates and then performing
Western blot analysis with an anti-ubiquitin antibody, we
detected a band whose size suggests that cytochrome c is
biubiquitinated even though determination of the number of
ubiquitins by electrophoretic positions is known to be inac-
curate (Jennissen, 1995; Pearce and Sherman, 1997). We per-
formed a mutational analysis, so excluding that Lys6, Lys8,
and Lys9 are the attachment sites for ubiquitin. Further
studies will be necessary to identify the ubiquitination sites
in mammalian cytochrome c.
It has been already reported that cells might have the
potential to recover after cytochrome c release (Martinou et
al., 1999; Deshmukh et al., 2000; Goldstein et al., 2000; Wa-
terhouse et al., 2001; Cozzolino et al., 2004). This matches the
observation that Apaf1 and caspase-9 (which act down-
stream of MOMP) deficiency can contribute to oncogenic
transformation. The overproliferation of Apaf1$/$ and
caspase-9$/$ proneurons in knockout mice indicates that
those cells, triggered to apoptosis, not only do not die but
are even able to proliferate (Cecconi et al., 1998; Kuida et al.,
1998; Soengas et al., 1999). In these studies, the point-of-no
return in cell death is considered the loss of !"m. The
maintenance of !"m after MOMP is necessary to provide
the cell with a continued source of energy and to maintain
mitochondrial functions. During the period over which
!"m is maintained, cells could be able to recover. However,
it has also been reported that this is possible only for a short
period after apoptotic induction; !"m loss eventually hap-
pens and this precedes a drop in ATP and cell death (Wa-
terhouse et al., 2001).
We wanted to extend over time the analysis of apopto-
some-impaired cells induced to die. We observed that after
both tunicamycin and actinomycin D treatment there is an
increase in ATP production. The increase in ATP production
after an apoptotic insult might be very likely due to need of
ATP for the apoptotic machinery (Zamaraeva et al., 2005). In
fact, even though in both ETNA$/$ and C9DNETNA cells
the apoptotic machinery is inhibited downstream of apop-
tosome formation, the apoptotic pathway proceeds regu-
larly until the step of cytochrome c release. On more ex-
tended observation, we noted that such cells are able to
maintain a normal metabolic activity (ATP generation and
production of reducing equivalents) even after a long treat-
ment, although !"m is apparently dissipated (Figures 4 and
5). Therefore, they can actively survive for about 6 d before
dying (Figures S2, S3, and S4). Under these conditions, ATP
generation and production of reducing equivalent are main-
tained by glycolysis (Figure 6, B and C). In fact, even though
oligomycin is added, cells keep in producing ATP, whereas
oligomycin addition, followed by glucose removal, abol-
ishes ATP production (Figure 6, B and C). The measurement
of mitochondrial respiration indicates that oligomycin addi-
tion does not inhibit, but only reduces respiration at a higher
extent in control cells ()35%) than in tunicamycin-treated
cells ()22%; see Figure S8).
In control ETNA$/$ and C9DNETNA cells, treatment
with oligomycin acutely hyperpolarizes mitochondria be-
cause the protonic gradient is not used to produce ATP,
because of the inhibition of the F0F1-ATPase by oligomycin
(Figure 5A). Surprisingly, we observed that oligomycin is
able to induce a recovery of !"m, not only in control cells
(Figure 5A, Ctrl) but also in apoptosome-impaired cells un-
der extended apoptotic treatment (Figure 5A, 48 h and 64 h).
Because !"m maintenance requires an intact inner mem-
brane (Mootha et al., 2001), our studies suggest that the
mitochondrial inner membrane is not irreversibly affected.
There could still be the possibility of restoring the proton
gradient across the mitochondrial inner membrane even
though cytochrome c has been released and mitochondria
are depolarized.
How could we explain the oligomycin-induced !"m re-
generation in tunicamycin-treated cells? This effect of oligo-
mycin is not due to inhibition of ATP synthesis, because
these cells do not produce ATP by oxidative phosphoryla-
tion (Figure 6). Moreover, oligomycin allows a partial resto-
ration of !"m in cells treated with tunicamycin even though
we block the respiratory chain with complex III (antimycin
A) or complex IV (KCN or NaN3) inhibitors (Figure 5B and
Figures S7 and S8). In principle, !"m might be regenerated
in the absence of respiratory chain activity by a mechanism
similar to the one functioning in rho zero cells. These cells
are depleted of mitochondrial DNA and, therefore, they do
not have a functional electron transport chain. It is generally
accepted that the !"m of mtDNA-depleted cells arises from
the electrogenic exchange of glycolytic ATP4$ for ADP3$
via the adenine nucleotide carrier ANT. Within the mito-
chondrial matrix, ATP4$ deriving from glycolysis is hydro-
lyzed by an intramitochondrial ATPase, probably an incom-
plete F1-ATPase (F0 is not functional in rho zero cells)
providing ADP3$, which is then exchanged with glycolytic
ATP4$ by ANT (Buchet and Godinot, 1998; Appleby et al.,
1999; Chandel and Schumacker, 1999; Arnould et al., 2003).
Oligomycin (which binds and inhibits only the F0 portion of
F0F1-ATPase) does not eliminate ATPase activity and !"m
in rho zero cells, because they are devoid of F0 (Buchet and
Godinot, 1998 Appleby et al., 1999). Based on this hypothe-
sis, the main source of !"m regeneration by oligomycin in
tunicamycin-treated cells would be the glycolytic ATP (Fig-
ure 8); we can speculate that the F1 subcomplex (insensitive
to oligomycin) might dissociate from the integral F0 portion
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(sensitive to oligomycin) of the F0F1-ATPase, thus rendering
F1 capable of ATP hydrolysis and F0 capable of oligomycin-
sensitive proton permeability. It is noteworthy that, in ab-
sence of oligomycin, mitochondria energization by a rho
zero-like mechanism in tunicamycin-treated cells is masked,
probably by proton leak through mitochondrial inner mem-
brane (Figure 5). Oligomycin can reveal this potential by
inhibiting the leak. However, further experiments are
needed to fully identify the cause of !"m regeneration in
tunicamycin-treated cells in the presence of oligomycin.
We have observed that (in contrast with antimycin and
KCN/NaN3) an ANT inhibitor, bongkrekic acid, reduces
membrane potential regeneration upon tunicamycin/oligo-
mycin treatment (Figure 5B). However, it does not abolish
completely mitochondria re-energization (Figure 5B, left
peak), so implying that other electrogenic pumps may also
be involved in this rho zero-like mechanism of !"m gener-
ation, as already proposed by other authors (Pereira-da-
Silva et al., 1993; Buchet and Godinot, 1998; Appleby et al.,
1999; Arnould et al., 2003).
Our study reveals that, in apoptosome-impaired cells
even after a prolonged toxic insult, depolarized mitochon-
dria do not reach a point-of-no-return. The inner mitochon-
drial membrane remains potentially functional after cyto-
chrome c release and even after !"m loss; it can still
compensate for ion leakage and allow a possible re-energi-
zation of mitochondria. Vice versa, oligomycin addition
upon apoptotic treatment cannot repolarize mitochondria
when also glycolysis is inhibited, even though Mpyr is sup-
plied (Figure 8, 48 h). Glycolysis is thus important for main-
taining the mitochondria potentially able to recover their
!"m, presumably because (under apoptotic stress and after
cytochrome c degradation) it is the only source of ATP,
which is necessary for !"m generation through a rho zero-
like mechanism. Our conclusions concern both kinds of cell
type, ETNA$/$ and C9DNETNA cells. This means that
there is no difference regarding the analyzed metabolic pa-
rameters when either Apaf1 or caspase-9 are impaired
within the apoptosome.
We have found out that the absence of glycolysis induces
an increased ROS production (Figure 9). ROS impair mito-
chondrial function by inactivating mitochondrial respiratory
chain complexes and by stimulating lipid peroxidation.
Lipid peroxides affect respiration, oxidative phosphoryla-
tion, maintenance of !"m, and inner membrane barrier
properties. In tunicamycin-treated cells (in which mitochon-
dria are already affected and depolarized) this can lead to
changes in the structure and function of the mitochondria
consistent with increased proton leakage and uncoupling of
mitochondria (Ott et al., 2007). Therefore, another reason for
the need of glycolysis to protect mitochondrial function,
besides the need of ATP to sustain !"m regeneration, is the
negative control of increased ROS production.
We have shown that, after cytochrome c release, the re-
covery of the cell is also possible, but only when glycolysis
is active and the apoptotic stimulus is removed within a
certain time range after induction (Figure 10), similarly to
what recently reported by Colell et al. (2007).
Finally, we observed that apoptosome-deficient cells un-
dergo autophagy soon after the apoptotic treatment. Most
important, we found that the role of glycolysis in contribut-
ing to cell survival for prolonged periods after cytochrome c
release depends on Beclin 1–regulated autophagy, this being
highly relevant for survival of apoptosome-deficient pro-
neurons under apoptotic stress. Autophagy plays a key role
in the bioenergetic management of starvation by generating
metabolic substrates that can be recycled and further pro-
cessed to maintain cellular ATP production (Levine and
Kroemer, 2008; Kotoulas et al., 2006). It has very recently
been shown that, in the absence of caspase activation, in-
creased glycolysis by GAPDH overexpression enhances re-
covery from MOMP and, consequently, cell survival (Colell
et al., 2007). This is probably due to the fact that increased
ATP production by glycolysis contributes in maintaining
!"m. In addition, the authors observe a GAPDH-enhanced
autophagy that contributes to cell survival probably by pro-
moting the removal of terminally damaged mitochondria
(Colell et al., 2007).
In particular, our experiments demonstrate that autoph-
agy, under cytotoxic stress, is necessary for the production
of ATP and for cell survival (Figure 11). This suggests that
recycling of cellular constituents through autophagy (fol-
lowed by their enzymatic breakdown in simple subunits) is
necessary to support glycolysis, for example, through deg-
radation of glycoproteins and glycogen autophagy (Elbein,
1991; Kotoulas et al., 2006). Moreover, lactic acid, most
amino acids, and glycerol can be converted into glucose via
the gluconeogenic pathway (occurring also in the brain);
also, degradation of nucleic acids releases ribose-1-phos-
phate, which can be transformed into intermediates of gly-
colysis (glyceraldehyde-3-phosphate and fructose-6-phos-
phate) by the pentoso-phosphate pathway (Gaitonde et al.,
1977; Rawn, 1998). Our findings help in clarifying the issue
of survival and recovery of apoptosome-inactivated cells
after mitochondrial permeabilization. Unraveling this issue
could have important implications for oncogenesis, because
recovery of transformed cells could be enhanced by apop-
tosome inactivation if autophagy is allowed. Moreover, such
discovery could have important consequences regarding the
survival and overproliferation of apoptosome-deficient neu-
rons, both of which, we have shown, depend not only on the
absence of the apoptosome but also on autophagic mecha-
nisms to sustain cell metabolism. This is important because
therapies based on transplantation of neural precursor cells
need to take into account not only the role of apoptosis but
also that of autophagy in their survival.
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